BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35244050)

  • 1. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
    Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
    Yang X; Min X; He W
    Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after helicobacter pylori eradication?
    Yamashita H; Watanabe H; Ajioka Y; Nishikura K; Maruta K; Fujino MA
    Histopathology; 2000 Aug; 37(2):131-40. PubMed ID: 10931236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
    Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
    Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
    Raderer M; Chott A; Drach J; Montalban C; Dragosics B; Jäger U; Püspök A; Osterreicher C; Zielinski CC
    Ann Oncol; 2002 Jul; 13(7):1094-8. PubMed ID: 12176789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.
    Streubel B; Ye H; Du MQ; Isaacson PG; Chott A; Raderer M
    Oncology; 2004; 66(6):476-80. PubMed ID: 15452377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.
    Chaudhary N; Ozer H; Huard D; Lightfoot S; Mesiya S
    Dig Dis Sci; 2006 Apr; 51(4):775-8. PubMed ID: 16615002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
    Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status.
    Nakamura T; Seto M; Tajika M; Kawai H; Yokoi T; Yatabe Y; Nakamura S
    Am J Gastroenterol; 2008 Jan; 103(1):62-70. PubMed ID: 17894851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial.
    Thiede C; Wündisch T; Neubauer B; Alpen B; Morgner A; Ritter M; Ehninger G; Stolte M; Bayerdörffer E; Neubauer A
    Recent Results Cancer Res; 2000; 156():125-33. PubMed ID: 10802872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Cencini E; Fabbri A; Schiattone L; Bocchia M
    Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
    [No Abstract]   [Full Text] [Related]  

  • 19. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.